OTC Disclosure & News Service
Share on Facebook Share on Twitter Share on LinkedIn
OTC Markets Group Welcomes Nuvilex to OTCQB
Aug 28, 2014
OTC Disclosure & News Service
New York, NY -
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Nuvilex, Inc. (OTCQB: NVLX) is verified for trading on OTCQB®, the venture marketplace for entrepreneurial and development stage companies, as of August 28, 2014.
Nuvilex is a clinical-stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the widely-used anticancer prodrug ifosfamide together with encapsulated live cells, which convert ifosfamide into its active or"cancer-killing" form. Nuvilex is also working towards clinical trials associated with the symptoms of advanced pancreatic cancer and other abdominal cancers.
Nuvilex's subsidiary, Medical Marijuana Sciences, is dedicated to the development of cancer treatments based upon chemical constituents of the cannabis plant known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or eliminating the debilitating side effects usually associated with traditional cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop “green” approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide every year.
bull
